• Please log in or register to access this feature.

Hepatobiliary Malignancies

You have full text access to this OnlineOpen article

Liver cancer: EphrinA2 promotes tumorigenicity through Rac1/Akt/NF-κB signaling pathway 120: †‡

  1. Yu-Xiong Feng1,5,§,
  2. Jiang-Sha Zhao1,5,
  3. Jing-Jing Li1,
  4. Tao Wang2,
  5. Shu-Qun Cheng2,
  6. Yunfei Yuan3,
  7. Fudi Wang1,
  8. Xiao-Fan Wang4,
  9. Dong Xie1,6,¶,*

Article first published online: 14 SEP 2009

DOI: 10.1002/hep.23313

Issue

Hepatology

Hepatology

Volume 51, Issue 2, pages 535–544, February 2010

Additional Information

How to Cite

Feng, Y.-X., Zhao, J.-S., Li, J.-J., Wang, T., Cheng, S.-Q., Yuan, Y., Wang, F., Wang, X.-F. and Xie, D. (2010), Liver cancer: EphrinA2 promotes tumorigenicity through Rac1/Akt/NF-κB signaling pathway 120: . Hepatology, 51: 535–544. doi: 10.1002/hep.23313

Author Information

  1. 1

    Laboratory of Molecular Oncology, Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, China

  2. 2

    The Eastern Hepatobiliary Surgery Hospital, the Second Military Medical University, Shanghai, China

  3. 3

    State Key Laboratory of Oncology in South China and Department of Hepatobiliary Surgery, Sun Yat-sen University Cancer Center, Guangzhou, China

  4. 4

    Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, NC

  5. 5

    Graduate School of Chinese Academy of Sciences, Shanghai, China

  6. 6

    Key laboratory of Nutrition and Metabolism, Chinese Academy of Sciences, Shanghai, China

  1. §

    These authors contributed equally to this study.

  2. fax: (86)-21-54920291

*Laboratory of Molecular Oncology, Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, 294 Tai-Yuan Rd. Shanghai 200031, China

  1. †

    Potential conflict of interest: Nothing to report.

  2. ‡

    This is a corrected version of the title first published on 16 November 2009 — the corrected version appears in print. In the originally published version, “akt” was misspelled as “ak”.

  3. §

    These authors contributed equally to this study.

  4. fax: (86)-21-54920291

Publication History

  1. Issue published online: 25 JAN 2010
  2. Article first published online: 14 SEP 2009
  3. Accepted manuscript online: 14 SEP 2009 12:00AM EST
  4. Manuscript Accepted: 29 AUG 2009
  5. Manuscript Received: 21 MAY 2009

Funded by

  • Ministry of Science and Technology Key program. Grant Numbers: 2008ZX10002-017, 863 Program 2007AA02Z4, 973 Program 2007CB914704
  • National Natural Science Funds for Distinguished Young Scholar. Grant Number: 30725010
  • National Natural Science Foundation of China. Grant Numbers: 90813023, 30528003
  • Chinese Academy of Sciences. Grant Numbers: KSCX2-YW-R-152, KSCX-YW-R-73
  • Science and Technology Commission of Shanghai Municipality. Grant Number: 08140902300

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article with Supporting Information (HTML) Get PDF (1878K)

References

  • 1
    Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer 2006; 118: 3030–3044.
  • 2
    Di Bisceglie AM, Carithers RL, Jr., Gores GJ. Hepatocellular carcinoma. HEPATOLOGY 1998; 28: 1161–1165.
  • 3
    El-Serag HB, Davila JA, Petersen NJ, McGlynn KA. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med 2003; 139: 817–823.
  • 4
    Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57–70.
  • 5
    Breuhahn K, Longerich T, Schirmacher P. Dysregulation of growth factor signaling in human hepatocellular carcinoma. Oncogene 2006; 25: 3787–3800.
  • 6
    Thaker PH, Deavers M, Celestino J, Thornton A, Fletcher MS, Landen CN, et al. EphA2 expression is associated with aggressive features in ovarian carcinoma. Clin Cancer Res 2004; 10: 5145–5150.
  • 7
    Pratt RL, Kinch MS. Activation of the EphA2 tyrosine kinase stimulates the MAP/ERK kinase signaling cascade. Oncogene 2002; 21: 7690–7699.
  • 8
    Zelinski DP, Zantek ND, Stewart JC, Irizarry AR, Kinch MS. EphA2 overexpression causes tumorigenesis of mammary epithelial cells. Cancer Res 2001; 61: 2301–2306.
  • 9
    Lu M, Miller KD, Gokmen-Polar Y, Jeng MH, Kinch MS. EphA2 overexpression decreases estrogen dependence and tamoxifen sensitivity. Cancer Res 2003; 63: 3425–3429.
  • 10
    Ogawa K, Pasqualini R, Lindberg RA, Kain R, Freeman AL, Pasquale EB. The ephrin-A1 ligand and its receptor, EphA2, are expressed during tumor neovascularization. Oncogene 2000; 19: 6043–6052.
  • 11
    Noren NK, Foos G, Hauser CA, Pasquale EB. The EphB4 receptor suppresses breast cancer cell tumorigenicity through an Abl-Crk pathway. Nat Cell Biol 2006; 8: 815–825.
  • 12
    Xia G, Kumar SR, Stein JP, Singh J, Krasnoperov V, Zhu S, et al. EphB4 receptor tyrosine kinase is expressed in bladder cancer and provides signals for cell survival. Oncogene 2006; 25: 769–780.
  • 13
    Iida H, Honda M, Kawai HF, Yamashita T, Shirota Y, Wang BC, et al. Ephrin-A1 expression contributes to the malignant characteristics of {alpha}-fetoprotein producing hepatocellular carcinoma. Gut 2005; 54: 843–851.
  • 14
    Hafner C, Schmitz G, Meyer S, Bataille F, Hau P, Langmann T, et al. Differential gene expression of Eph receptors and ephrins in benign human tissues and cancers. Clin Chem 2004; 50: 490–499.
  • 15
    Cheng HJ, Nakamoto M, Bergemann AD, Flanagan JG. Complementary gradients in expression and binding of ELF-1 and Mek4 in development of the topographic retinotectal projection map. Cell 1995; 82: 371–381.
  • 16
    Davenport RW, Thies E, Zhou R, Nelson PG. Cellular localization of ephrin-A2, ephrin-A5, and other functional guidance cues underlies retinotopic development across species. J Neurosci 1998; 18: 975–986.
  • 17
    Hattori M, Osterfield M, Flanagan JG. Regulated cleavage of a contact-mediated axon repellent. Science 2000; 289: 1360–1365.
  • 18
    Gallo G, Yee HF, Jr., Letourneau PC. Actin turnover is required to prevent axon retraction driven by endogenous actomyosin contractility. J Cell Biol 2002; 158: 1219–1228.
  • 19
    Jurney WM, Gallo G, Letourneau PC, McLoon SC. Rac1-mediated endocytosis during ephrin-A2- and semaphorin 3A-induced growth cone collapse. J Neurosci 2002; 22: 6019–6028.
  • 20
    Fox BP, Kandpal RP. Invasiveness of breast carcinoma cells and transcript profile: Eph receptors and ephrin ligands as molecular markers of potential diagnostic and prognostic application. Biochem Biophys Res Commun 2004; 318: 882–892.
  • 21
    Giannelli G, Pierri F, Trerotoli P, Marinosci F, Serio G, Schiraldi O, et al. Occurrence of portal vein tumor thrombus in hepatocellular carcinoma affects prognosis and survival. A retrospective clinical study of 150 cases. Hepatol Res 2002; 24: 50.
  • 22
    Nakazaki H. Preoperative and postoperative cytokines in patients with cancer. Cancer 1992; 70: 709–713.
  • 23
    Luedde T, Liedtke C, Manns MP, Trautwein C. Losing balance: cytokine signaling and cell death in the context of hepatocyte injury and hepatic failure. Eur Cytokine Netw 2002; 13: 377–383.
  • 24
    Hill MM, Hemmings BA. Inhibition of protein kinase B/Akt. implications for cancer therapy. Pharmacol Ther 2002; 93: 243–251.
  • 25
    Nakada M, Drake KL, Nakada S, Niska JA, Berens ME. Ephrin-B3 ligand promotes glioma invasion through activation of Rac1. Cancer Res 2006; 66: 8492–8500.
  • 26
    Arsura M, Cavin LG. Nuclear factor-kappaB and liver carcinogenesis. Cancer Lett 2005; 229: 157–169.
  • 27
    Chiao PJ, Na R, Niu J, Sclabas GM, Dong Q, Curley SA. Role of Rel/NF-kappaB transcription factors in apoptosis of human hepatocellular carcinoma cells. Cancer 2002; 95: 1696–1705.
  • 28
    Andres AC, Ziemiecki A. Eph and ephrin signaling in mammary gland morphogenesis and cancer. J Mammary Gland Biol Neoplasia 2003; 8: 475–485.
  • 29
    Sawai Y, Tamura S, Fukui K, Ito N, Imanaka K, Saeki A, et al. Expression of ephrin-B1 in hepatocellular carcinoma: possible involvement in neovascularization. J Hepatol 2003; 39: 991–996.
  • 30
    Noren NK, Lu M, Freeman AL, Koolpe M, Pasquale EB. Interplay between EphB4 on tumor cells and vascular ephrin-B2 regulates tumor growth. Proc Natl Acad Sci U S A 2004; 101: 5583–5588.
  • 31
    Kumar SR, Masood R, Spannuth WA, Singh J, Scehnet J, Kleiber G, et al. The receptor tyrosine kinase EphB4 is overexpressed in ovarian cancer, provides survival signals and predicts poor outcome. Br J Cancer 2007; 96: 1083–1091.
  • 32
    Yoshioka K, Kakumu S, Arao M, Tsutsumi Y, Inoue M. Tumor necrosis factor alpha production by peripheral blood mononuclear cells of patients with chronic liver disease. HEPATOLOGY 1989; 10: 769–773.
  • 33
    Yoshioka K, Kakumu S, Arao M, Tsutsumi Y, Inoue M, Wakita T, et al. Immunohistochemical studies of intrahepatic tumour necrosis factor alpha in chronic liver disease. J Clin Pathol 1990; 43: 298–302.
  • 34
    Old LJ. Tumor necrosis factor (TNF). Science 1985; 230: 630–632.
  • 35
    Aggarwal BB. Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol 2003; 3: 745–756.
  • 36
    Lucas R, Kresse M, Latta M, Wendel A. Tumor necrosis factor: how to make a killer molecule tumor-specific? Curr Cancer Drug Targets 2005; 5: 381–392.
  • 37
    Schmitz KJ, Wohlschlaeger J, Lang H, Sotiropoulos GC, Malago M, Steveling K, et al. Activation of the ERK and AKT signalling pathway predicts poor prognosis in hepatocellular carcinoma and ERK activation in cancer tissue is associated with hepatitis C virus infection. J Hepatol 2008; 48: 83–90.
  • 38
    Nakanishi K, Sakamoto M, Yamasaki S, Todo S, Hirohashi S. Akt phosphorylation is a risk factor for early disease recurrence and poor prognosis in hepatocellular carcinoma. Cancer 2005; 103: 307–312.
  • 39
    Brantley-Sieders DM, Caughron J, Hicks D, Pozzi A, Ruiz JC, Chen J. EphA2 receptor tyrosine kinase regulates endothelial cell migration and vascular assembly through phosphoinositide 3-kinase-mediated Rac1 GTPase activation. J Cell Sci 2004; 117: 2037–2049.
  • 40
    Jin S, Ray RM, Johnson LR. Rac1 mediates intestinal epithelial cell apoptosis via JNK. Am J Physiol Gastrointest Liver Physiol 2006; 291: G1137–G1147.
View Full Article with Supporting Information (HTML) Get PDF (1878K)